Article Text

Download PDFPDF
PKP-019 Pharmacological interactions registered with the use of new direct acting antiviral agents for treatment of hepatitis C virus
  1. MJ Gándara Ladrón de Guevara,
  2. C Palomo Palomo,
  3. E Ríos Sánchez,
  4. JC García de Paredes Esteban,
  5. M Cameán Castillo,
  6. MA Blanco Castaño,
  7. S Fénix Caballero,
  8. J Díaz Navarro,
  9. C Martínez Díaz,
  10. JM Borrero Rubio
  1. Hospital Puerto Real, Hospital Pharmacy, Cádiz, Spain


Background The direct acting antiviral agents (DAA) may present a high percentage of pharmacological interactions and may compromise the effectiveness and safety of these treatments.


  • To describe the pharmacological interactions registered between home treatment and DAA for the treatment of hepatitis C virus.

  • To analyse the therapeutic groups involved and to assess the acceptance of pharmaceutical recommendations.

Material and methods A descriptive study was conducted from January to September 2015. Patients treated with DAA and active home treatments were included. Demographic data, pharmacological interactions and acceptance of pharmaceutical recommendations were collected. The interactions were consulted in the European Public Assessment Report, hep-drug interactions and Micromedex. The pharmaceutical recommendations were classified as: ‘A’, these drugs should not be coadministered; B’, potential interaction, may require close monitoring, alteration of drug dosage or timing of administration; and ‘C’, no clinically significant interaction expected.

Results 143 patients were included (98 men), and 359 pharmacological interactions were consulted. Most were no clinically significant interaction ‘C’, 238 (66.3%), but 90 (25%) were ‘B’ (potential interaction) and 31 (8.7%) were ‘A’ (interaction where it was recommended not to coadminister).

The pharmaceutical recommendations, therapeutic groups involved and DAA are shown in table 1.

Abstract PKP-019 Table 1

OBV/PTV/r: ombitasvir/paritaprevir/ritonavir.


  • The DAA reported a high percentage of pharmacological interactions, but most did not need pharmaceutical recommendations. The majority of them were ‘B’, only a small percentage were ‘A’. The recommendations given were accepted and implemented.

  • The antiretroviral treatments present the greatest possibility of interactions, and a comprehensive individual treatment review was still necessary.

  • The pharmacist is crucial in detecting and reporting pharmacological interactions, and in defining the recommendations to follow.

References and/or Acknowledgements All authors

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.